Patent intelligence · AU
AU 2001289696
New use of lipase inhibitors
New use of lipase inhibitors
Patent details — AU 2001289696
- Jurisdiction
- AU
- Status
- granted
- Grant date
- Jul 6, 2006
- Expiration
- Jul 1, 2026
- Applicant
- CHEPLAPHARM ARZNEIMITTEL GMBH [DE]
- CPC classes
- A61K 31/ 00 A I, A61K 31/ 16 A I, A61K 31/ 21 A I, A61K 31/ 337 A I
Quick answer
AU 2001289696 (New use of lipase inhibitors) is held by CHEPLAPHARM ARZNEIMITTEL GMBH [DE]. Status: granted. Granted Jul 6, 2006. Expires Jul 1, 2026 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- CHEPLAPHARM ARZNEIMITTEL GMBH [DE]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 31/ 00 A I, A61K 31/ 16 A I, A61K 31/ 21 A I, A61K 31/ 337 A I, A61K 31/ 365 A I, A61K 31/ 717 A I
More from CHEPLAPHARM ARZNEIMITTEL GMBH [DE]
Related pharmaceutical patents in our USPTO index.
-
AU 2007332640
Powder formulation for valganciclovir
granted -
AU 2001289699
New pharmaceutical composition
expired -
AU 2002212120
Lipase inhibitors for the treatment of dyspepsia
expired -
AU 2001281846
Method for preparing a composition
expired -
AU 2002319189
Pharmaceutical compositions comprising orlistat and fatty acids and/or salts thereof
expired -
AU 2002257817
Pharmaceutical composition comprising a lipase inhibitor and a sucrose fatty acid ester
expired -
AU 2003222814
PHARMACEUTICAL COMPOSITION COMPRISING A LIPASE INHIBITOR AND GLUCOMANNAN
expired
Frequently asked questions
What is US patent 2001289696?
AU 2001289696 (New use of lipase inhibitors) is held by CHEPLAPHARM ARZNEIMITTEL GMBH [DE]. Status: granted. Granted Jul 6, 2006. Expires Jul 1, 2026 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns AU 2001289696?
CHEPLAPHARM ARZNEIMITTEL GMBH [DE] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 10 pharmaceutical patents for this assignee.
When does AU 2001289696 expire?
Our index shows an expiration date of Jul 1, 2026 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.